12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aliskiren: Phase III discontinued

Novartis discontinued the double-blind, placebo-controlled, international Phase III ALTITUDE trial in 8,606 Type II diabetics with renal impairment after an independent DMC concluded that patients were "unlikely to benefit" from the addition of once-daily 300 mg aliskiren to standard of care (SOC) anti-hypertensive treatment. Additionally, aliskiren plus SOC led to...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >